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ABSTRACT 
Disruption of E-cadherin (CDH1 gene) expression, subcellular localization or function arises during 
initiation and progression of almost 90% of all epithelial carcinomas. Nevertheless, the mechanisms 
through which this occurs are largely unknown. Previous studies showed the importance of CDH1 intron 
2 sequences for proper gene and protein expression, supporting these as E-cadherin cis-modulators. 
Through RACE and RT-PCR, we searched for transcription events arising from CDH1 intron 2 and 
discovered several new transcripts. One, named CDH1a, with high expression in spleen and absent from 
normal stomach, was demonstrated to be translated into a novel isoform, differing from canonical E-
cadherin in its N-terminal, as determined by mass-spectrometry. Quantitative and functional assays 
showed that when overexpressed in an E-cadherin negative context, CDH1a replaced canonical protein 
interactions and functions. However, when co-expressed with canonical E-cadherin, CDH1a increased 
cell invasion and angiogenesis. Further, interferon-induced genes IFITM1 and IFI27 levels were increased 
upon CDH1a overexpression. Effects on invasion and IFITM1 and IFI27 expression were reverted upon 
CDH1a specific knockdown. Importantly, CDH1a was de novo expressed in gastric cancer cell lines. This 
study presents a new mechanism by which E-cadherin functions are impaired by cis-regulatory 
mechanisms possibly with the involvement of inflammatory machinery. If confirmed in other cancer 
models, our data encloses potential for designing targeted therapies to rescue E-cadherin function. 
 
Keywords: E-cadherin/CDH1, isoform, gastric cancer, invasion and angiogenesis. 
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INTRODUCTION 
E-cadherin, a protein encoded by the CDH1 gene [ENSG00000039068] is the dominant epithelial cell 
adhesion molecular and plays a crucial role in epithelial tissue polarity and structural integrity (1) (2). 
Reduced cell-cell adhesiveness allows cancer cells to disobey their local (social) order, resulting in the 
destruction of histological structure; the most prominent morphological hallmark of malignant tumors (3). 
The most clinically relevant point in the progression of 90% or more carcinomas is believed to be 
mediated by disruption of normal E-cadherin expression, subcellular localization or function (4) (5). 
Classical gene inactivation (mutation, gene loss and promoter hypermethylation), transcriptional and post-
transcriptional mechanisms (transcription repressors, RNA and protein quality control) have all been 
associated with E-cadherin loss and/or deregulation of its localization and function, in a wide range of 
epithelial tumors (6-12). Despite the strong correlation between E-cadherin loss and malignancy, the 
mechanism through which this occurs is not known for most sporadic and hereditary epithelial 
carcinomas.  
Although mutations and deletions of CDH1 remain the unique germline defects described in 47% of 
hereditary diffuse gastric cancer (HDGC; OMIM No. 137215) (13, 14), more than 70% of all HDGC 
families present germline monoallelic expression imbalance at the RNA level (10), caused by so far 
undetected mechanisms. The later observation is consistent with the overall E-cadherin protein expression 
defects found in most HDGC tumors (13) and pinpoint the key role of CDH1 in this hereditary syndrome. 
The scenario in sporadic gastric cancers is somewhat similar, as approximately 90% of the cases present 
aberrant or absent E-cadherin protein expression and unequivocal gene inactivating mechanisms occur 
only in 30% of the cases (15). 
While seeking for mechanisms regulating CDH1 expression during mouse development, Stemmler and 
colleagues (2003 and 2005) showed that murine CDH1 intron 2 deletions interfere with gene 
transcriptional activation and expression in a tissue specific manner (16, 17), strongly supporting the 
existence of sequences, within those regions, that may act as cis-modulators of E-cadherin expression 
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(18). Thus, there are unaccounted mechanisms for CDH1 inactivation in sporadic and inherited tumors, 
potentially involving intronic-dependent regulation of this locus. 
 
The specificity and complexity of gene expression patterns in cells and tissues is achieved not only by 
increases and decreases in expression levels of cell-specific genes, but also through alternative splicing, 
alternative transcription initiation, alternative polyadenylation and RNA editing (19). Recent uses of RNA 
sequencing (RNA-seq) have been pivotal to unveil transcript quantification, assess alternative splicing 
and detect novel gene structures. This overwhelming and increasing diversity on mRNA population 
occurs because 95-100% of all human pre-mRNAs, that contain sequences corresponding to more than 
one exon, are processed to yield multiple mRNAs (20, 21). Several of these new transcripts are known to 
regulate the canonical RNA form by many different mechanisms (22, 23). As an example, a recent paper 
suggests that an alternative PTK6 transcript is able to negatively regulate growth and modulate PTK6 
activity, protein-protein associations and/or subcellular localization (24). To date similar findings have 
not been reported for CDH1, as no transcripts alternative to the canonical are described, besides those 
resulting from exon skipping events in cancerous samples. Herein, we describe transcripts arising from 
within CDH1 intron 2, and address their putative role as modulators of E-cadherin expression and 
function in cancer cells. 
 
RESULTS 
In the present work, we intended to understand whether novel long transcripts arise from within intron 2 
of CDH1, to characterize their expression pattern and to ascribe their putative role as modulators of E-
cadherin expression, localization and function.  
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CDH1 locus gives rise to several transcripts in addition to the canonic 
Our working hypothesis was that novel exons overlapping with annotated ESTs within intron 2 could be 
initiating exons of new CDH1 transcripts. To address this, we have analyzed CDH1 expression upstream 
and downstream of intron 2 in several normal human tissues by Real-time PCR and using TaqMan assays 
covering exon 1-2 and exon 6-7 borders. Interestingly, the expression ratio (exon 6-7)/(exon 1-2) was 
higher than 1 for all normal tissues analyzed suggesting increased transcription levels downstream of 
CDH1 intron 2 (Fig. 1). This increased transcription was highest for peripheral blood lymphocytes 
(PBLs) followed by spleen, where exon 6-7 probe expression was 2-fold higher when compared to exon 
1-2 levels.  
The information from Public databases (UCSC Genome Browser http://genome.ucsc.edu/ and Ensembl 
http://www.ensembl.com) was used to retrieve the available information on the CDH1 locus. Four 
transcripts are currently annotated at Ensembl database for CDH1: the canonic transcript and other three 
transcripts either including one additional canonical exon or excluding one or three canonical exons. 
Importantly for the present work, none of the annotated transcripts encompass intron 2 sequences. Several 
overlapping expressed sequence tags (ESTs) are annotated for CDH1 intron 2, potentially indicating that 
transcription from this locus could be more complex than previously anticipated (Fig. 2). As spleen was 
one of the tissues with higher (exon 6-7)/(exon 1-2) expression ratio, we used commercial spleen RNA to 
test the existence of CDH1 transcripts encompassing any of the selected ESTs, and their splicing with 
further downstream CDH1 exons. Among EST’s tested, we identified two new exons, encoded by intron 
2 sequences, each splicing with exon 3 at its canonical splice-site (Fig. 2). These two novel transcripts 
were called CDH1a and CDH1b (Fig. 2). Moreover, when amplifying CDH1a, we systematically verified 
the appearance of a higher molecular weight band that, upon sequencing, revealed to be another 
transcript, named CDH1j. A similar scenario was verified for CDH1b, where another splice-site was 
identified 10-bp upstream of the one initially recognized. This variant was coined CDH1b-10 (Fig. 2). All 
four new transcripts were found to splice with the canonical exon 3 splice-site and to include all 
 at IN
SERM
 on July 4, 2012
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
6 
 
downstream CDH1 canonical exons (Fig. 2), as determined by primer-walking PCR (data not shown). 
Additionally, only CDH1a and CDH1b-10 were found to have in-frame initiation codons (AUG). CDH1a 
presents a competent Kozak sequence upstream of the AUG (data not shown) in contrast to the one from 
CDH1b-10. We have also assessed the polyadenylation status of these transcripts and inquired about the 
DNA strand from which they were derived. CDH1a and CDH1j were found to be polyadenylated 
contrarily to CDH1b and CDH1b-10 (data not shown). All were found to arise from the sense strand. 
In order to determine the transcription start site (TSS) of novel CDH1 transcripts, we used spleen and 
stomach 5’ RACE-ready cDNA libraries (built from polyadenylated RNA). These tissues were chosen for 
this purpose because spleen, as a non-epithelial tissue, is described to lack canonical E-cadherin 
expression and presented a high (exon 6-7)/(exon 1-2) CDH1 expression ratio, indicating the presence of 
additional transcripts. Differently, in stomach, an epithelial tissue, E-cadherin canonical expression is well 
recognized and was shown to have a low (exon 6-7)/(exon 1-2) expression ratio (Fig. 1). Using this 
strategy, we observed that, in spleen, CDH1a and CDH1j represented more than half of the total 
polyadenylated RNA molecules amplified. Additionally, we observed the existence of two additional 
transcripts, one starting in intron 1 (CDH1Seq1) and other in exon 3 (CDH1Seq5, that probably 
corresponds to the Ensembl annotated transcript, ENST00000422392 - Ensembl release 61 - Feb 2011). 
As expected, the canonical CDH1 transcript was not detected in spleen (Fig. 2). For stomach, the 
canonical transcript was the main RNA form found (45%), although transcripts starting in intron 1 
(CDH1Seq1) and exon 3 (CDH1Seq11-13), similar to those identified in spleen, were also identified in 
stomach, the remaining CDH1a, CDH1j, CDH1b and CDH1b-10 were not found (Fig. 2 and 
Supplementary Figure 1).  
For CDH1a, two 5’-sequences upstream of the same in-frame AUG were recurrently identified 
(CDH1Seq2 and CDH1Seq3 in Fig. 2) and therefore assumed as two different TSSs. The presence of 
these was further confirmed when its sequence was compared with CAGE data extracted from the Encode 
Project database at UCSC genome browser (http://genome.ucsc.edu/). For CDH1j transcript, the right 
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location of potential TSSs was harder to infer, due to high variation in the length of sequences obtained 
by 5´RACE. This transcript is most probably a non-coding RNA, due to lack of identifiable AUG with a 
long open-reading frame and Kozak sequence. CDH1b and CDH1b-10 transcripts, shown earlier to be 
non-polyadenylated, were not found in this 5’-RACE experiment (Fig. 2). 
 
The sequence of novel CDH1 exons overlaps or is in close vicinity of genomic regulatory features and 
conserved non-coding sequences. 
Approximately 15% of all CDH1 transcripts in spleen and 60% in stomach start within or upstream of 
CDH1 intron 1. These transcripts, together with CDH1Seq10 from stomach (Fig. 2), overlap a CpG island 
that is well known to modulate the expression of the canonical transcript as first described by Berx et al 
(1995) (2). Thus, similarly to the canonical transcript, the expression of these novel transcripts may also 
be influenced by methylation at this CpG island. Additionally, a First Exon (EF) element is predicted to 
overlap the initial exon of the canonical transcript (exclusive of stomach), and the novel exon encoded by 
a portion of intron 1 belonging to a transcript that is present in both tissues studied (Fig. 2). The presence 
of this element and its proximity to the latter novel exon encoded by intron 1 (CDH1Seq1), indicates that 
this exon is likely the first exon of a novel CDH1 transcript.  
Several DNAse I hypersensitive sites, which are commonly associated with new areas of transcription 
and/or gene regulation, were annotated in the vicinity of CDH1a and CDH1b sequences (25) (Fig. 2). 
Moreover, an AluSc repeat was found to overlap the sequence of the longer form of CDH1a that encodes 
the CDH1j transcript, likely indicating an Alu-mediated exonization event (26) (Fig. 2). 
At the beginning of the canonical exon 3, a predicted CCCTC-binding factor (CTCF) binding site was 
also found, what may be important to explain the percentage of RNA transcripts starting immediately 
downstream of this site in stomach (~40%) and in spleen (~15%) (Fig. 2). 
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Fig. 2 was constructed based both on several tracks of UCSC and the Ensembl Genome Browser and our 
own data and depicts in detail the data described above. 
We also investigated the extent of mammalian sequence conservation for the CDH1a and CDH1j 
transcripts identified. We verified the nucleotide level GERP score (27) for each transcript, focusing only 
on the novel portion (i.e. the part of the transcript that had not been previously reported). As shown in 
Supplementary File 1, CDH1a transcripts appear to be evolutionarily constrained, with mammalian 
sequence conservation across most of their sequence in line with that of UTR portions of genes (median 
GERP score 1.72, max GERP score=3.67 for both the longer CDH1a_70 transcript and shorter 
CDH1a_34 transcript). CDH1j, on the other hand, shows a very different conservation pattern. The 
median GERP score indicates that there is no long-range evolutionary constraint across the transcript, but 
the sliding window analysis indicates clearly that the final portion of the CDH1j exon is highly conserved 
(nt 320-352), which has a median GERP score of 2.3. Interestingly the highly conserved portion also 
corresponds to the DNAase I hypersensitivity site. 
 
CDH1a expression is tissue-specific 
We characterized CDH1a in detail as, unlike the other CDH1 novel transcripts, it has cumulatively a 
polyadenylated open-reading frame encoding a novel 5’-exon transcribed from within intron 2, 
encompasses two possible TSSs, an adequate Kozak consensus sequence upstream of the AUG, and 
splices with the canonical exon 3, sharing all downstream exons with the CDH1 canonical transcript. This 
RNA transcript encloses most of the necessary features to be translated into a protein isoform and is also 
particularly interesting because it is the most abundant CDH1 transcript in spleen (~50%) and is 
completely absent in stomach, according to the 5’-RACE results. 
Using PCR followed by Q-SnapShot (10), we addressed CDH1a pattern of expression in several normal 
tissues. We have confirmed high CDH1a expression for spleen and its absence in stomach (Fig. 3A), 
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contrasting with the scenario obtained for CDH1 canonical transcript (Fig. 2). Although highest CDH1a 
expression levels have been found for spleen, other normal tissues displayed variable expression of the 
transcript. Interestingly, the expression of CDH1a in PBLs was not comparable to that observed when 
measuring the (exon 6-7)/(exon 1-2) expression ratio depicted in Fig. 1 which indicates that this is likely 
due to the expression of other transcripts starting downstream of exon 2 in PBLs. 
Given that CDH1a mRNA levels were high for spleen, no canonical transcript was present and no other 
open-reading frames were identified by 5’-RACE, we reasoned that if a protein isoform was being 
produced from this transcript, it would be caught by immunohistochemistry using an antibody against any 
portion of the canonical protein, encoded by exons downstream of exon 3. For that, we stained both 
normal human spleen and stomach sections with an E-cadherin antibody that recognizes the protein (E-
cadherin and putative CDH1a isoform) cytoplasmic domain. In spleen, we observed a very specific and 
localized staining pattern (Fig. 3B), in contrast to the typical staining of the canonical E-cadherin at the 
basolateral surface of adjacent cells in gastric glands (Fig. 3C). Although fairly similar to small blood 
vessels in aspect, the stained structures observed in spleen showed no co-localization with CD34, a 
marker of endothelial cells (Suppl. Fig. 1). Together, these observations support that CDH1a is translated 
and encodes a novel E-cadherin isoform in spleen. 
 
Exogenous overexpression of CDH1a generates a protein that is less efficiently processed to a mature 
form than canonical E-cadherin  
In order to assess CDH1a protein isoform translation and potential processing, we cloned the full 
transcript sequence from the AUG to the stop codon in a Lentiviral derived expression vector (pLenti, 
Invitrogen). Empty vector (Mock) and the vector carrying canonical CDH1 cDNA (E-cadherin) were also 
generated as negative and positive controls, respectively. The Chinese Hamster Ovary (CHO) cell line 
was chosen to be transduced due to its complete lack of E-cadherin expression. The predicted aminoacidic 
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differences between E-cadherin and CDH1a sequences are depicted in figure 4A. The canonic sequence 
MetGPWSRSLSAL…RHLERGRVLGR transcribed from the exon 1 and 2 sequences is replaced by 
MetKLKLSRKQIQHGDKAAAVSLL, the aminoacids encoded by the new exon 1a. Through western 
blot and using an antibody capable of detecting both the canonical and also CDH1a isoforms (Fig. 4A), 
we were able to prove the effectiveness of transduction and to confirm that, upon lentiviral promoter 
influence, CDH1a is efficiently translated into a protein of approximated size to that of the canonical E-
cadherin (Fig. 4B). As expected, the empty vector (Mock) cells did not induce E-cadherin expression.  
Since the immature form of E-cadherin is predictably processed to its mature form by cleavage of the 154 
aminoacid residues precursor sequence, we analyzed whether CDH1a isoform would be cleaved in a 
similar way. Using brefeldin A, that blocks the transfer of the protein to the Golgi complex and its 
processing (28), we verified for both (CDH1a isoform and E-cadherin), bands corresponding to the 
mature proteins displayed comparable molecular weight, whereas the immature proteins did not. This 
result confirms that CDH1a pre-protein is smaller than the canonical E-cadherin and further that the two 
proteins are cleaved, if not at the same site, in very close proximity (Fig. 4C).  
To confirm the relative amount of mature and immature proteins between cells expressing the canonical 
or the CDH1a protein isoform, we proceeded to protein sequencing by mass spectrometry using bands 
extracted from the gel (Fig. 4E). Protein lysates were immunoprecipitated using an anti-E-cadherin 
antibody and the resulting eluate was separated by 1D SDS-PAGE from both CHO E-cadherin and CHO 
CDH1a expressing cell lines. For each cell line two bands with different molecular weights were 
observed, possibly related with E-cadherin immature (higher molecular weight) and mature (lower 
molecular weight) forms as seen in Fig. 4C. For CHO E-cadherin, both bands were identified by MALDI-
TOF/TOF mass spectrometry as E-cadherin with a C.I. of 100% (Supplementary Table 2). Thirty peptides 
were found to be associated to E-cadherin (UniProt accession ID P12830) from CHO E-cadherin, both in 
higher and lower molecular weight mass.  
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CDH1a bands also presented 19 peptides associated with E-cadherin (Uniprot accession ID P12830) that 
were common to the canonical E-cadherin. In addition, an extra peak was identified with a mass of 
1722.85Da, that was absent for CHO E-cadherin (Suppl. Fig. 2). To verify that this novel peak was 
associated with CDH1a N-terminus, we downloaded the Swiss-Prot/UniProt protein sequence database 
and manually inserted the full CDH1a sequence. A Mascot Peptide Mass FingerPrint (PMF) analysis 
successfully associated this 1722.85Da peak as well as identified a smaller one with 953.52Da with 
CDH1a sequence, corresponding, respectively, to the N-terminal peptides  AAAVSLLVNFEDC*TGR 
16-31 (C*, carbamidomethylation of cysteine) and KQIQHGDK 8-15 (Supplementary Table 2). To 
further validate this result, the 1722.85Da peak, which presented the best signal to noise ratio, was 
subjected to MS/MS peptide sequencing followed by a PMF+MS/MS combined analysis. A Mascot ion 
score of 99.9% was obtained for this peptide (Supplementary Table 2). Peptide sequencing was not 
possible for the smaller peak (953.52Da), nevertheless its presence is consistent in the two bands analyzed 
and specific from CDH1a expressing cells (two independent replicas).  
It is also worth noting that, for the lower molecular weight E-cadherin band, presumably indicating the 
mature form (Fig. 4E), the combination of the first 3 N-terminal peptides (aa 55 to 74), observed after 
tryptic digestion, are decreased 8.8-fold in E-cadherin and the first 4 N-terminal peptides (aa 8 to 42) 
decrease 3.5-fold in CDH1a when compared with all the other peptides (Supplementary Table 2). This 
indicates that CDH1a processing is 2.5 (8.8/3.5) times less efficient than E-cadherin processing. In the 
immature E-cadherin and CDH1a higher molecular weight bands, the intensity of the peptide peaks 
associated with the protein’s N-terminal does not significantly change, when compared with the peptide 
peaks associated with other regions of E-cadherin, as expected when the processing is efficient. 
The results obtained for both E-cadherin isoforms confirm their identity and reveal that CDH1a is less 
efficiently processed to a mature form than canonical E-cadherin, but are not sufficient to determine the 
potential sites of cleavage for each isoform. They show, nevertheless, that CDH1 and CDH1a encode two 
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distinct proteins with different N-terminal regions that, independently of the processing, exist in the cell 
with potentially different functions.  
 
CDH1a isoform mimics canonical E-cadherin localization, adhesion complex interactions, cell-
adhesion and invasion suppression properties when overexpressed in canonical E-cadherin-negative 
cells  
To assess CDH1a function, we conducted immunoprecipitation in protein extracts from cells expressing 
CDH1a (and the canonical form, for positive control) using the same anti-E-cadherin antibody, followed 
by western blot for proteins that classically interact with E-cadherin to form the adhesion complex (β-
catenin and p120ctn). Our results demonstrate the effective binding of both proteins to these catenins 
(Fig. 4D) and are further supported by immunofluorescence results showing that CDH1a is able to induce 
β-catenin (Fig. 4E) and p120-catenin (Fig. 4F) recruitment to the cell membrane. This argues towards the 
putative functionality of CDH1a protein in establishing an effective adhesion complex. Moreover, we 
observed that CDH1a, similarly to E-cadherin, was able to confer aggregation capacity to the otherwise 
non-aggregating CHO cells (Fig. 4G) and to reduce the intrinsic invasion levels of parental CHO cells 
(Fig. 4H). Overall, these results show that CDH1a isoform, when expressed alone, mimics the canonical 
E-cadherin function. 
 
CDH1a promotes cell invasion and angiogenesis when co-expressed with the canonical E-cadherin 
We next addressed the CDH1a induced expression effect in cells endogenously producing functional E-
cadherin. For that, we chose the gastric cancer derived cell line MKN28. Due to suboptimal proportion of 
MKN28 CDH1a expressing cells, using the pLenti vector, we subcloned CDH1a and the canonical CDH1 
into a pIRES2-EGFP vector that expresses our protein of interest and GFP in the same cell. This approach 
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allowed sorting GFP positive cells and monitoring transfection efficiency which reached around 90% 
(Fig. 5A and B). Overexpression from either the canonical E-cadherin or CDH1a has not produced visible 
alterations in the overall E-cadherin expression levels or cellular localization, as ascertained by 
immunocytochemistry (Fig. 5C).  
We confirmed mRNA overexpression of the canonical CDH1 or CDH1a using the previously described 
strategy, where exon 1-2 probe expression measures specifically canonic transcript expression and exon 
6-7 expression measures overexpression of both transcripts. As expected, an increase in canonic CDH1 
mRNA expression was detected by both probes, for cells transfected with the canonical CDH1 expression 
vector in comparison to Mock cells; whereas an increase in CDH1a mRNA overexpression was detected 
only by the Exon 6-7 probe (Fig. 5D).  
Surprisingly, the results obtained by western blot did not mimic the previous RNA expression data, since 
similar levels of E-cadherin protein were detected for the three cell lines (Fig. 5E). To unveil whether the 
excess of translated protein, due to the forced production of high levels of mRNA from both isoforms, 
was being degraded, we treated the three cell lines with MG132, a proteasome function inhibitor. We 
confirmed that this was the case, as significantly increased protein levels were detected both in E-cadherin 
and CDH1a overexpressing cells (P=.001 and P=.020, respectively) in contrast to Mock cells, after the 
treatment with this drug (Fig. 5F).  
Assuming that the proteasome blindly degrades both isoforms in CDH1a overexpressing cells, a 
proportion of the detected protein by western blot and immunohistochemistry is expected to be the 
CDH1a isoform. Moreover, in CDH1a overexpressing MKN28 cells, high amounts of unprocessed 
CDH1a seem to occur, as shown by the abnormal superior thickening of the western blot signal (Figure 
5F). In contrast to canonical CDH1 overexpressing MKN28 cells, separation between the upper and the 
main lower band (presumably the mature processed form) is not clear, due to the smaller difference 
between the unprocessed and processed proteins when compared to the canonical form. 
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To prove this, we have repeated mass spectrometry analysis and showed that the CDH1a specific peaks 
(953.52Da and 1722.85Da) are found in MKN28 CDH1a overexpressing cells (Supplementary Table 3 
and 4). 
Next, we carried out aggregation, motility and invasion experiments to access the effect of concomitant 
expression of the two isoforms. We verified that CDH1a overexpression increased cell aggregation 
capacity in comparison with Mock cells, nevertheless this augmented aggregation ability was lower than 
that induced by the canonic isoform (Fig. 6A). No differences were found in motility levels for the three 
cell lines (data not shown), which contrasted with results obtained for the invasion assay. CDH1a 
overexpression in MKN28 cells led to a significant increase in the number of invasive cells when 
compared to cells overexpressing E-cadherin or the empty vector (Fig. 6B). Taken together, these data 
indicates that CDH1a overexpression induced less efficient cell aggregation, did not affect cell motility 
but conferred an invasive phenotype to otherwise poorly invasive cells. No differences were observed in 
the three cell lines regarding cell proliferation or apoptosis (data not shown). 
We further tested the effect of CDH1a overexpression in MKN28 cells regarding tumor induced 
angiogenesis, using the classical chick embryo chorioallantoic membrane (CAM) in vivo model (29-31). 
The angiogenic response levels were quantified by counting the number of novel radial blood vessels 
formed in tumors induced by every cell line, and verified that tumors formed by CDH1a overexpressing 
cells were the ones eliciting significantly more blood vessels when compared with cells transfected with 
the empty vector (Fig. 6C and D). By pan-cytokeratin immunoexpression, we confirmed that tumors 
growing in the CAM were exclusively formed by the human cells (Fig. 6E) and demonstrated by PCR 
that these maintain CDH1 and CDH1a overexpression patterns (Suppl. Fig. 3).  
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CDH1a overexpression in MKN28 cells increases IFITM1 and IFI27 mRNA levels  
In order to determine the effect of CDH1a overexpression on the overall mRNA expression pattern of 
pLenti transduced MKN28 cells, we performed a genome-wide mRNA expression array analysis. This 
experiment identified 50 genes (76 probes) whose expression was upregulated and 33 genes (42 probes) 
whose expression was downregulated (Suppl. Fig. 4 and Suppl. File 3). In Supplementary Table 5, we 
have presented the 24 most altered (positively or negatively) genes, from which we selected preferentially 
upregulated genes for qRT-PCR validation. The eight genes with top fold-change and lower P-values 
were tested as well as two of the top downregulated genes. We were able to confirm IFN-induced 
transmembrane protein 1 (IFITM1) and IFI27 overexpression by qRT-PCR, specifically in cells 
overexpressing CDH1a (Fig. 7A and B) while for the other genes no consistent results were found (Suppl. 
Fig. 5). IFITM1 levels were also upregulated upon CDH1a overexpression in HEK cells (data not shown). 
We performed Ingenuity analysis on the list of significant differentially expressed genes to select the 
functional classes (defined as network) overrepresented. The highest Ingenuity scoring networks contain 
the most statistically robust candidates for hypothesis building. Inflammatory response result to be the 
most significant network in our analysis (Suppl. Fig. 6, see also Suppl. File 3). Interestingly, 4 out of 15 
genes of the network known to be involved in gastric cancer are present in the list of differentially 
expressed. The other significant networks overrepresented in CDH1a responsive genes are cellular growth 
and proliferation, cellular movement, cancer and cell death (Suppl. file 2). Through a PGSEA analysis, 
the TGF-β pathway was predicted to be upregulated in MKN28 CDH1a cells when compared to controls 
(Suppl. Fig. 7). 
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Invasion levels are restored and IFITM1 and IFI27 are lowered upon siRNA-mediated CDH1a 
downregulation 
In order to definitively demonstrate that the observed increases in invasion, and IFITM1 and IFI27 
expression levels are driven by CDH1a overexpression, we designed a specific siRNA to target 
specifically this transcript. A 35% reduction in CDH1a levels (Fig. 8A) was sufficient to lower 
significantly invasion levels by 73% (Fig. 8B) and IFITM1 and IFI27 by 31% and 45%, respectively. 
Canonical CDH1 expression displayed no alteration (Fig. 8C).  
 
CDH1a transcript is overexpressed in gastric cancer cell lines 
Having observed the CDH1a potentially deleterious effects over canonical E-cadherin function, and given 
that CDH1a mRNA was not expressed in normal stomach, we tested its expression in gastric cancer 
derived cell lines along with canonical E-cadherin expression. Interestingly, we observed an inverse 
correlation between CDH1a and canonical CDH1 mRNA expression in normal stomach and gastric 
cancer cell lines (Fig. 9A and B). While the canonical form was highly expressed in normal stomach and 
presented an overall downregulation in gastric cancer cell lines, CDH1a mRNA was absent in normal 
stomach, as previously observed, and overexpressed in most gastric cancer cell lines (Fig. 9A and B). 
Moreover, most gastric cancer cell lines were found to co-express the canonical CDH1 and CDH1a 
mRNAs. 
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DISCUSSION 
Loss of the epithelial adhesion molecule E-cadherin is thought to be the earliest and one of the most 
important steps in metastatic dissemination of epithelial cancer (7, 32). Although impairment of E-
cadherin gene and protein expression has been the subject of many studies, the causes for this disruption 
are, in many cases, unknown and the mechanisms so far described insufficient. It is possible that driver 
events for this impairment could be embedded in the genomic structure of the CDH1 gene itself. The 
pioneer studies by Stemmer and colleagues (16, 17) showed that regulation at the CDH1 locus can be 
driven by powerful yet unidentified regulatory sequences with the 65kb intron 2 of this gene. In the 
present study, we studied novel and conserved coding intron 2 sequences, and described the tissue 
specificity and potential biological function of one of them. 
This is, to the best of our knowledge, the first report specifically addressing CDH1 alternative 
transcription, besides the alternative splicing variants, involving canonical exons, deposited in public 
databases. After proving that the mRNA sequences downstream of intron 2 were more represented in 
several normal tissues than those upstream of this intron, we tested whether annotated Expressed 
Sequence Tags (ESTs) within CDH1 intron 2 could be transcribed into novel CDH1 exons. Two of these 
ESTs were shown to encompass novel exons able to splice with exon 3, sharing the remaining exons and 
termination with the canonic sequence. Both exons are targets of alternative splicing and each new exon 
generates at least one in-frame transcript and one long-noncoding RNA. This finding reveals the existence 
of novel E-cadherin transcripts in normal contexts. Somewhat surprisingly, spleen, that was shown not to 
express canonical transcript, expresses high levels of CDH1a, a novel protein encoding transcript that 
localizes at the cell membrane of structures from the splenic red medulla. 
We were further able to map important genomic elements overlapping or near the novel transcription 
units herein described, such as a CpG island, Dnase I hypersensitive sites and a CTCF binding site, that 
re-enforce their significance and potential function (Fig. 2). CpG islands are regions commonly found 
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near transcription start sites and frequently associated with promoter regions. This fact constitutes 
evidence towards the possible regulation of novel transcripts through promoter methylation, as happens 
for the canonic CDH1 transcript. Dnase I hypersensitive sites, uncovered by ChIP-Seq experiments 
(UCSC Genome Browser tracks) tend to be near active genes, which are regularly transcribed (25). At the 
beginning of CDH1 exon 3 a predicted CCCTC-binding factor (CTCF) is found (UCSC Genome Browser 
tracks), which characteristic insulator function (33, 34) may justify the low percentage of RNAs starting 
after this region in stomach. Here, as an epithelial tissue, E-cadherin is known to exert well-established 
functions and must be, therefore, tightly regulated. This would allow preventing putative deleterious 
effects from the concomitant expression of other transcripts from the CDH1 locus. In contrast, for spleen, 
as non-epithelial tissue, CDH1 locus may somehow be more loosely controlled originating a broader 
variety of coding and noncoding transcripts of thus far uncertain functional relevance. Interestingly, one 
of the noncoding transcripts (CDH1j, depicted as Seq4 in Fig. 2B) was found to encompass an AluSc 
repeat. The Alu family is composed of over one million repetitive elements of about 300 base pairs long 
that are interspersed throughout the human genome and embrace more than 10% of it (9, 35). Alu repeats 
have been implicated in the etiology of rearrangement based deleterious mutations reported of CDH1 and 
other genes (9). In addition, such transposable elements have been shown to cause alternative splicing by 
providing the 5’ or 3’ splicing sites in so-called “exonization events” (36).  Other regulatory mechanisms 
also involving Alu elements have been recently reviewed (37). 
Overall evidence indicated that while CDH1a is a bona fide novel protein coding transcript while the 
other transcripts identified are more likely to play a role at non-coding level. The conservation analysis 
underlined this difference, since CDH1a showed constant overall conservation, while CDH1j showed a 
conservation pattern which is more typical of enhancer like elements, with short blocks of high 
conservation. Transcribed enhancers have been shown to exist extensively, especially across highly 
conserved elements (38), thus it is possible that CDH1j is a transcribed enhancer. 
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We further characterized one of the novel transcripts, CDH1a, selected because it possesses a long ORF, 
an adequate Kozak sequence, is polyadenylated and is therefore predicted to encode a novel E-cadherin 
protein isoform. We then determined that CDH1a, an isoform that differs from the canonical one only at 
the most N-terminal residues, which were predicted to be cleaved from the mature form of the protein, 
could work as a negative modulator of the canonical E-cadherin function. This kind of effect has been 
previously described (23).  
We were able to show that CDH1a isoform, driven by a pLenti vector, gave rise to a mature protein 
similar in size to the canonic. As expected, the size of the immature form was found to be smaller since 
canonic exons 1 and 2 are replaced by a new exon (exon 1a) in CDH1a. CDH1a was able to replace the 
canonical protein function, in that its protein location at the membrane, partner interactions co-localizing 
with β-catenin and p120-ctn, aggregation induction and invasion suppression properties when expressed 
on its own match those of canonical E-cadherin. These data imply that, in the absence of the canonic E-
cadherin, its functions may be accomplished by the new isoform herein described. Nevertheless, there are 
differences between E-cadherin and CDH1a, as two N-terminal specific peptides from the latter 
(953.52Da and 1722.85Da) were detectable by mass spectrometry in CDH1a expressing cells. These 
peptides potentially constitute good targets for antibody design to better disclose CDH1a expression 
pattern. 
Interestingly, the behavior induced by CDH1a expression alone, was not mimicked when CDH1a was 
expressed in a context of endogenous canonical E-cadherin expression. In this setting, canonic protein 
localization was not impacted to a perceivable extent, but CDH1a forced expression led to moderate 
aggregation impairment and significantly increased angiogenic potential and invasion levels. Invasion 
increase was reverted upon CDH1a targeting through specific siRNA. A similar observation has been 
recently described in breast cancer derived cell lines (39). These authors showed that co-expression of P-
cadherin and canonical E-cadherin in MCF7 cells promoted invasion in vitro, while their counterparts 
expressing either molecule alone would remain non-invasive. The effect of CDH1a may be comparable in 
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that CDH1a overexpression hampers E-cadherin normal function despite the cells epithelial phenotype is 
maintained. When we overexpressed CDH1a in E-cadherin expressing cells no increase in protein levels 
was observed unless we treated cells with a proteasome inhibitor. This led to a significant augment in 
total protein levels, implying that total protein levels are controlled by the ubiquitin-proteasome 
machinery (40, 41), over a given expression threshold. We therefore hypothesize that the observed 
consequences at the functional level in cells co-expressing CDH1a and the canonical form, can only occur 
if the cell blindly degrades both isoforms and not only CDH1a. The co-existence of both molecules, 
despite their similarities and expression at the right amounts, provides cancer cells with an advantageous 
invasive phenotype. The means by which this phenotype is achieved is not known, although our 
experiments indicate that CDH1a is less efficiently processed than E-cadherin. It is possible that the extra 
peptides in the mature CDH1a determine the effects observed either directly or indirectly through a 
number of genes with altered expression levels, upon CDH1a overexpression, as revealed by our 
expression microarray analysis. This experiment identified 50 upregulated genes and 33 downregulated. 
We performed Ingenuity analysis on the list of significant differentially expressed genes to select the 
functional classes (defined as network) overrepresented. The highest Ingenuity scoring networks 
containing the most statistically robust candidates for hypothesis building indicated the Antimicrobial 
Response, Inflammatory Response and Infectious Disease network as the most significant, despite others 
have also putatively interesting results.  Importantly 4 out of 15 genes from the network known to be 
involved in gastric cancer are present in the list of differentially expressed. Since our previous results 
were indicative of gain of function effects, we gave greater importance to upregulated genes. We have 
therefore selected the eight genes with higher fold-change and lower P-values, when comparing MKN28 
CDH1a overexpressing cells with controls, for qRT-PCR validation. We have selected also two 
downregulated genes. Possibly due to the different vectors used to establish cells for the array experiment 
and qRT-PCR validation we had a low level of concordance between both techniques. This, however, 
strengthens the results obtained for IFITM1 and IFI27 genes. These were the only genes with 
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upregulation validated by qRT-PCR (besides CDH1) and interestingly they are part of the above referred 
network. CDH1a siRNA treatment led to the downregulation of both IFITM1 and IFI27.  
IFITM1 is a member of the IFN-inducible transmembrane protein family and its involvement in the 
migratory and invasive potential of gastric cancer cells is well established, supporting our data (42). It 
was established that IFITM1 induces tumor resistance to NK cells in gastric tumor cells, being 
hypothesized that it behaves like a surface molecule utilized by tumor cells for immune escape and 
migration, making of IFITM1 a possible therapeutic target for the treatment of gastric cancer. Recently, 
IFITM1 was implicated in the invasive front of early invasive and advanced HNSCC (43, 44) and its 
knockdown has been shown to significantly inhibit migration and invasion of glioma cells (44). 
IFI27 was identified in breast carcinoma cell lines (45) and belongs to a family of small, interferon-alpha 
(IFN-α)-inducible genes. Suomela S et al proposed IFI27 as a novel marker of epithelial proliferation and 
cancer due to its upregulation in cutaneous squamous cell cancers (46) as confirmed later (47).  
A Parametric Gene Set Enrichment Analysis (PGSEA), that allows the analysis of gene expression data to 
determine deregulation of gene signatures or “molecular concepts”, suggested that CDH1a overexpression 
in canonical E-cadherin expressing cells could impact the TGF-β pathway.  
We observed that when compared to control cell lines, CDH1a overexpressing cells have upregulation of 
the transforming growth factor-β (TGF-β) pathway, which has a well-recognized dual role both in tumor 
initiation and progression (48) and in tumor suppression (49, 50). The mechanisms of tumor promotion by 
TGF-β include increased angiogenesis. The impact of CDH1a overexpression on the latter was seen 
through a marked increase in angiogenesis in the chick embryo chorioallantoic membrane (CAM) model. 
It is therefore possible that this induction of angiogenesis is triggered by TGF-β pathway upregulation, 
although the mechanism through which this pathway is activated remained elusive after the expression 
array performed. Other pathways enclosed by the networks revealed by the Ingenuity analysis might, as 
well, be implicated in this angiogenic effect of CDH1a. 
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Since stomach was the only normal tissue in this study lacking endogenous CDH1a expression, we 
decided to search for its de novo expression in gastric cancer derived cell lines. Interestingly, and in 
contrast to what was observed for normal stomach, most expressed CDH1a. This indicates that 
transcription arising from CDH1 locus may be deregulated in the gastric cancer context, resulting in the 
co-expression of both the canonic transcript and CDH1a, possibly leading to the deleterious effects 
mentioned above (Fig. 10). Despite many efforts, we were not able to identify CDH1a isoform 
endogenous expression in MKN28 nor in other gastric cancer cell lines. The reason for this inability may 
be explained by a recent report that has shown that proteins with deleterious effects when overexpressed 
have lower abundances than the normal protein due to shorter half-lives (51). Additionally these proteins 
are predicted to display higher structural disorder (52, 53) and the severity of deleterious phenotype is 
strongly associated with percent of disorder (51). In a cancer context, the ability of a cell to control the 
relative amounts of proteins with deleterious functions is predictably reduced and therefore negative 
consequences are more prone to arise. The way a protein is deleterious is not unique. A protein may carry 
specific domains that by themselves, or through their interactions, are toxic. Other proteins show high 
intrinsic disorder, which is likely to be associated with their deleterious effect. Yet others are tightly 
regulated, and are likely to perturb cellular homeostasis when the dynamics of their expression is 
disrupted. At the moment we cannot put forward which applies for CDH1a although our results seem to 
favor the last hypothesis. 
In summary, our work describes, for the first time, tissue-specific coding and noncoding CDH1 
transcripts arising from new exons encoded by intron 2 sequences, and highlights a possible novel 
mechanism underlying epithelial cancer cell invasion and angiogenesis. It is possible that the unique 
CDH1a peptides described and the potential effectors IFITM1 and IFI27 could become therapeutic targets 
and that isoform-specific antibodies could be designed to target CDH1a-mediated cancer invasion and 
angiogenesis.  
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MATERIALS AND METHODS 
Biological samples and cell lines 
In order to perform transcripts quantification we have purchased commercial total RNA from several 
normal tissues: spleen (Ambion), stomach (Ambion), colon (Stratagene) and breast (Stratagene). 
Regarding thyroid and peripheral blood lymphocytes (PBLs) we have pooled several samples from 
normal controls available at IPATIMUP. We have quantified CDH1a and the canonical transcript in RNA 
samples from MKN28, MKN45, GP202, SNU1, SNU638, KATOIII, AGS, IPA220 and NCI-N87 gastric 
cancer cell lines, available at the IPATIMUP’s repository.  The cell lines used for transduction and 
transfection experiments were: 1) the Chinese Hamster Ovary (CHO) cell line, as a cadherin-free cell line, 
and; 2) the human gastric cancer derived MKN28, as a model with normal and functional E-cadherin. 
Normal stomach and spleen tissues used for immunohistochemistry were obtained from paraffin blocks 
from the Hospital S.João tissue bank (Porto, Portugal) and VU University Medical Center (Amsterdam, 
The Netherlands). Chicken fertilized eggs for the angiogenesis assay were acquired from commercial 
sources (Granja Santa Isabel, Spain). 
Bioinformatics 
Using the Ensembl database (http://www.ensembl.org, version 64, September 2011 (54) and the UCSC 
Genome Browser (http://genome.ucsc.edu, NCBI36/hg18 (50) we have collected data on several genomic 
elements predicted/annotated within CDH1's intron 2 genomic locus: 1) CpG islands (49, 54); 2) EF 
(First Exon Finder) elements (54, 55); 3) Alu repeat elements (54, 56); 4) CTCF (CCCTC-binding factor) 
sites (34, 54); 5) DNAse I Hypersensitive Sites (49, 56); 6) EST (Expression Sequence Tags) from the 
database dbEST (54, 57)  and; 7) CAGE (Cap Analysis Gene Expression) tags from the ENCODE project 
(58, 59). CAGE data collected refers to those obtained using the "normal" lymphoblastoid cell line 
GM12878 and the leukaemia cell line K562. RNA populations analysed include total RNA and polyA 
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negative RNA. Subcellular compartments analysed include nucleus, cytosol, nucleoplasm, polysome and 
chromatin (60).  
Using the annotated Expression Sequence Tags (EST) present in the UCSC Genome Browser 
(http://genome.ucsc.edu/cgi-bin/hgTracks), we have designed primers to amplify specifically new areas of 
transcription. 
To assess CDH1a and CDH1j sequence conservation, the nucleotide level GERP score (27) was 
downloaded from the UCSC genome browser, using the start and end coordinates of the novel portion of 
the transcript identified (i.e. excluding the known protein-coding portion of CDH1), as shown in 
Supplementary File 1. The data was then assessed both at the single nucleotide level (first column in the 
table), as well as using a 10bp sliding window (second column in the table and shown also as graph). 
Overall conservation was indicated by verifying the average, median, minimum and max GERP score 
observed across the entire region. Local conservation for CDH1j was investigated by searching for blocks 
which presented more than 10nt with GERP score >1, highlighted in yellow in the table. The table also 
contains a UCSC screenshot showing GERP score, transcription score based on ENCODE RNA-Seq data, 
and ENCODE DNAase I hypersensitivity regions. 
RNA isolation and cDNA synthesis 
RNA Isolation was performed using the Tripure Isolation Reagent (Roche). RNA quality was verified 
using the NanoDrop ND-1000 (Thermo Scientific) for confirmation of acceptable 260/280 nm absorbance 
ratio as well as determining sample concentrations. Subsequent first-strand cDNA synthesis was done 
using approximately 1µg of total RNA with Superscript II Reverse Transcriptase and random hexamer 
primers (Invitrogen) following the company protocol.  
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Quantitative RT-PCR 
Expression levels were assessed using TaqMan Gene Expression Assays. Further details are available at 
Supplementary Material and Methods.  
Rapid Amplification of cDNA Ends (RACE)  
We have acquired and used stomach and spleen FirstChoice® RLM-RACE Kit (Ambion) according to 
manufacturer’s instructions. Briefly, we have submitted RACE ready cDNA to a first round of 
amplification using a 5’ RACE outer primer and an outer exon 4 CDH1 primer, followed by a second 
round using another set of primers. Products were cloned and sequenced. More details are available at 
Supplementary Material and Methods. All sequences thus obtained were analysed and compiled: the 
spleen FirstChoice® RLM-RACE Kit revealed 6 distinct types of sequences, 2 of which were very similar 
hence summed in one (seq4); the stomach FirstChoice® RLM-RACE Kit revealed 8 distinct types of 
sequences. Data on the coordinates of each sequence (after performing Blast analysis against the human 
genome (54) is presented on Supplementary Table 1.  
Quantitative-SnapShot (Q-SNapShot) 
CDH1a quantification was performed by Q-SnapShot (10). Further details on Supplementary Material 
and Methods. 
Primer walking PCR 
This strategy was used to characterize the full sequence of transcripts studied. The primers used for the 
sequential amplification steps are available upon request. 
Plasmids construction and virus production 
The human E-cadherin nucleotide sequence as reported in the literature (2), was cut from the pcDNA3 
plasmid described earlier (61) and cloned into a pLenti6/V5 Directional TOPO® (Invitrogen) giving rise 
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to the CDH1 expression vector. The sequence of exons 1 and 2 was later replaced by exon 1a. These 
vectors, along with the empty vector were used to transduce CHO cells. Viruses were produced following 
the company instructions. pIRES vectors were subsequently constructed using the above mentioned 
inserts. Further details are available at Supplementary Material and Methods.  
Cell culture, transduction, brefeldin-A and MG132 treatment 
CHO and MKN28 cells were grown using standard conditions. These conditions as well as the brefeldin-
A and MG132 treatments are described in detail at Supplementary Material and Methods.  
Cell sorting and flow cytometry 
Stable CHO and MKN28 cells were sorted in a Coulter Epics XL-MCL flow cytometer (Beckman 
Coulter) using the anti-E-cadherin HECD1 (Zymed Laboratories) and endogenous GFP expression, 
respectively, in order to obtain a homogeneous population of expressing cells. GFP flow cytometry was 
performed for MKN28 cells to monitor transfection levels across the course of experiments. Detailed 
protocol available at Supplementary Material and Methods. 
Antibodies, immunofluorescence, immunohistochemistry and microscopy 
Antibodies and detailed conditions are available at Supplementary Material and Methods.  
Slow aggregation assay and matrigel invasion assay 
Cell aggregation assays were performed by coating the wells of a 96-well-plate with 50µL of an agar 
solution with subsequent cell seeding. Aggregation was evaluated at 24, 48 and 72hr under an inverted 
microscope.  
For CHO and MKN28 cells invasion assays, Matrigel invasion chambers (BD Biosciences) were used 
according to the manufacturer conditions. Details are available at Supplementary Material and Methods.  
SDS–PAGE, western blotting and immunoprecipitation 
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Total protein lysates have been used for all experiments. Standard conditions have been employed as 
described in detail in the Supplementary Material and Methods.  
Proteomic analysis 
After E-cadherin enrichment by immunoprecipitation, proteins were separated by SDS-PAGE using 3μg 
of total protein. Following SDS-PAGE separation, proteins were stained, excised and MS and MS/MS 
peptide mass spectra were acquired with a MALDI-TOF/TOF 4700 Proteomics Analyzer. Detailed 
description is available at Supplementary Material and Methods.  
Chicken embryo in vivo angiogenesis assay 
The chicken embryo chorioallantoic membrane (CAM) model was used to evaluate angiogenic response 
of MKN28 parental and engineered cell lines. The number of new vessels growing radially towards the 
ring area was counted in a blind fashion. Further details are available at Supplementary Material and 
Methods. 
CDH1a siRNA treatment 
A custom CDH1a specific siRNA was designed (IDT). Briefly, cells were seeded into 6-well plates and 
grown in standard conditions until transfection with 100nM of CDH1a siRNA with Lipofectamin 2000 
following manufacturer’s instructions. After 60hrs we proceeded to invasion assays as described earlier. 
Remaining cells were used for RNA extraction, CDH1a, IFITM1 and IFI27 quantification by real-time 
PCR. A non-silencing siRNA (ThermoScientific) was used as negative control. 
Gene expression array 
Biotinylated cRNA targets were synthesized from each sample and hybridized to Affymetrix 
oligonucleotide chips according to manufacturers’ instruction (Affymetrix Inc.). GeneChips® Human 
Genome U133 Plus 2.0 containing 54.000 probe sets (47,000 transcripts and variants including 38,500 
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well-characterized human genes) were used. The data discussed in this publication have been deposited in 
NCBI's Gene Expression Omnibus (62) and are accessible through GEO Series accession number 
GSE32540 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32540). Details concerning the 
analysis of data are available at Supplementary Material and Methods. 
Statistical analysis 
R statistical program was used for the construction of standard boxplots, plotted with whiskers and 
outliers calculated with a maximum of 1.5 IQR.  Due to the non-normal distribution of the data, a non-
parametric test, in particular the Wilcoxon Rank Sum Test was used to calculate significance. The P-
values obtained were further corrected by using the Bonferroni Correction due to the multiple testing 
performed. Corrected P-values <0.05 were considered statistically significant. 
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Legends to figures 
Figure 1. CDH1 qRT-PCR expression ratio using two probes targeting different gene regions, exon 
6/7 and exon 1/2 boundaries. Normal tissues were tested and all presented higher expression levels with 
the downstream probe indicating the existence of transcripts encompassing exons 6-7 but excluding exons 
1-2 
Figure 2. CDH1 gene locus gives rise to several transcripts in addition to the canonic. A. CDH1* 
indicates the canonical transcript and CDH1ş designates the novel transcripts herein described. ESTs are 
the Expressed Sequence Tags deposited in the dbEST database for CDH1 gene. Genomic elements 
represent the features annotated for this genome location: CpG indicates the existence of a CpG island; 
EF is the site where the first exon of a given transcript is predicted to be located; AluSc signifies the 
existence of a Alu repeat from the Sc subcategory in the region; DNaseI represents DNase I 
hypersensitive sites detected by ChIP-Seq and; CTCF means the prediction of a CCCTC-binding factor 
(CTCF) binding site. Zoom in pictures of shaded areas I and II are represented in the lower panel. B. 
RACE (spleen) and RACE (stomach) describe the sequences that resulted from our Rapid Amplification of 
cDNA Ends experiments and are depicted in the pie charts that summarize the results obtained. 
Figure 3. CDH1a is highly expressed in normal spleen and is detected with an anti-E-cadherin 
antibody. A. Q-SnapShot expression of CDH1a transcript in normal tissues. Spleen has the highest level 
of CDH1a expression and stomach presents no expression. B and C. Immunohistochemistry performed 
with an anti-E-cadherin antibody targeting a common region between CDH1a and the canonic transcript 
in sections of normal paraffin embedded spleen and stomach tissues. B. In spleen, a non-epithelial tissue 
(without canonic E-cadherin expression), the antibody stains unidentified globular structures formed by 
small groups of cells. C. Gastric epithelial expression displays the expected pattern with the staining at the 
basolateral surface of adjacent cells. Scale bars: upper panel - 200 µm and lower panel – 100 µm. 
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Figure 4. CDH1a is translated, in vitro, into an E-cadherin isoform that interacts with β- and p120 
catenins at the membrane of CHO (E-cadherin-negative) cells and elicits cell aggregation and invasion 
suppression. A. Schematic representation of the canonic protein and from the putative CDH1a isoform. In 
dark and light grey areas are the specific regions from both proteins, respectively. The white corresponds 
to the common part that is predicted to be cleaved during protein processing that occurs at the site marked 
by a grey line. The black area corresponds to the expected mature proteins and the asterisk marks the 
epitope recognized by the antibody used. B. CDH1a mature protein has a similar size to the canonic E-
cadherin. C. CDH1a immature form is, as expected, smaller than the canonic protein as exons 1 and 2 are 
replaced by exon 1a. D. CDH1a is able to bind to β-catenin and p120ctn, components of the adhesion 
complex as happens with the canonic E-cadherin protein. E. Coomassie blue stained gel showing E-
cadherin and CDH1a processed and unprocessed bands. F and G. CDH1a isoform recruits and co-
localizes with β-catenin and p120ctn at the cell membrane as occurs for E-cadherin. No staining is 
observed for mock transfected cells. Scale bar – 15 µm. H. CDH1a isoform is able to elicit cell-cell 
aggregation as for E-cadherin, in contrast to the empty vector (mock) transduced cells. Scale bar – 200 
µm. I. CDH1a confers statistically significant strong invasion suppression capacity as the canonic protein 
when compared to mock cells (P=.026 and .019, respectively). 
Figure 5. CDH1a overexpression in E-cadherin expressing MKN28 cells does not interfere with 
canonic protein localization. A. Flow cytometry was performed to monitor MKN28 transfection 
efficiencies of pIRES_E-cadherin, Mock and CDH1a constructs. B. GFP fluorescence levels of MKN28 
E-cadherin, Mock and CDH1a cells. Scale bar – 15 µm. C. E-cadherin immunofluorescence of MKN28 
E-cadherin, Mock and CDH1a cells. Overexpression of the transcripts has not influenced normal 
membrane protein localization. Scale bar – 15 µm. D. QRT-PCR levels with two assays targeting 
different regions, 1-2 and 6-7 CDH1 exon boundaries. As expected, CDH1 overexpression results in 
higher levels of expression for both probes while for CDH1a only the second assay detects increased 
transcription levels. E. E-cadherin Western blot reveals an equivalent level of protein expression in each 
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cell line. F. E-cadherin Western blot of MG132 treated cells shows that transfection results in an effective 
increase in protein translation that is masked by proteasome degradation. 
Figure 6. CDH1a overexpression promotes mild MKN28 (E-cadherin positive cells) aggregation and 
increases invasion and angiogenesis levels. A. Slow aggregation assay showing that MKN28 E-cadherin 
cells aggregate more compactly than mock cells, as expected. Interestingly, CDH1a cells present 
intermediate compaction. Scale bar – 3 mm. B. Invasion assay demonstrates significantly higher levels in 
MKN28 CDH1a in comparison both to MKN28 Mock and CDH1 cells. C. CAM angiogenesis assay 
shows an increase in blood vessels formation between MKN28 Mock and MKN28 CDH1 cells. CDH1a 
led to a significant increase in angiogenesis when compared to Mock cells. D. CAM angiogenesis assay 
images showing the ring used for cell inoculation, the tumor formed and blood vessels nurturing the 
tumor. Scale bar – 1 mm. E. Pan-cytokeratin immunohistochemistry of a CAM section showing the 
chorion (ch) and the allantoic (al) sides of the membrane. Scale bar – 400 µm. 
Figure 7. CDH1a overexpression in MKN28 cells increases IFITM1 and IFI27 levels. A and B. 
MKN28 CDH1a overexpressing cells display significant IFITM1 and IFI27 gene expression upregulation 
when compared to controls. 
Figure 8. Invasion, IFITM1 and IFI27 levels are reduced upon CDH1a specific downregulation. A. 
MKN28 CDH1a overexpressing cells were treated with a specific siRNA leading to 35% of knockdown 
when compared to the non-silencing siRNA. B. Invasion levels were reduced in 73% after siRNA 
treatment. C. IFITM1 and IFI27 levels were also reduced by 31% and 45%, respectively.     
Figure 9. CDH1a transcript is overexpressed in gastric cancer cell lines.  A. Stomach qRT-PCR 
expression of CDH1 and CDH1a transcripts. Cell lines present high expression heterogeneity when 
compared with stomach values, although the majority express lower CDH1 levels than the normal tissue. 
B. Q-SNapShot CDH1a expression levels show that this transcript is completely absent in normal 
stomach but de novo in most of the gastric cell lines tested.  
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Figure 10. CDH1a effect model in gastric cancer cell lines.  In normal stomach only E-cadherin is 
expressed from the CDH1 locus. This protein is expressed at the cell membrane where it exerts its main 
function being responsible for cell-cell adhesion. In gastric cancer cell lines CDH1a isoform is produced 
from the CDH1 locus. This isoform is expressed at the cell membrane where it impairs normal E-cadherin 
function as seen by adhesion and invasion assays. Gene expression array and qRT-PCR revealed IFITM1 
and IFI27 mRNA upregulation. Moreover, in CAM assay, angiogenesis is induced upon CDH1a 
overexpression. 
 
Abbreviations: HDGC, Hereditary Diffuse Gastric Cancer; DGC, Diffuse Gastric Cancer; GC, Gastric 
Cancer; PBLs, Peripheral Blood Lymphocytes. 
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